Neuren Pharmaceuticals Limited has released a press release.
Growing royalty anchors Neuren first ever dividend program
Earlier from Neuren Pharmaceuticals
- European Commission grants marketing authorisation for DAYBU
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
- DAYBU recommended for approval in the European Union
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025